Celcuity Inc. unveils new data on gedatolisib for advanced breast cancer in investor presentation

Reuters

11/14

<a href="https://laohu8.com/S/CELC">Celcuity Inc</a>. unveils new data on gedatolisib for advanced breast cancer in investor presentation

Celcuity Inc. has released new data from its Phase 3 VIKTORIA-1 clinical study evaluating gedatolisib in patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer. The study showed that gedatolisib combinations met both primary endpoints by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. Specifically, the triplet combination of gedatolisib, fulvestrant, and palbociclib achieved a median progression-free survival (mPFS) of 9.3 months versus 2.0 months for fulvestrant alone, reflecting a 7.3-month improvement. The company plans to submit a New Drug Application for the PIK3CA wild-type cohort in the fourth quarter of 2025. Celcuity is also advancing clinical trials of gedatolisib in other cancer types, including metastatic castration-resistant prostate cancer. As of the third quarter of 2025, the company reported cash and investments of $455 million, projected to fund operations through 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583263548"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583263548\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583263548?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 06:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583263548","market":"us","top_or_hot":-1,"title":"Celcuity Inc. unveils new data on gedatolisib for advanced breast cancer in investor presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a>. unveils new data on gedatolisib for advanced breast cancer in investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Celcuity Inc. has released new data from its Phase 3 VIKTORIA-1 clinical study evaluating gedatolisib in patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer. The study showed that gedatolisib combinations met both primary endpoints by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. Specifically, the triplet combination of gedatolisib, fulvestrant, and palbociclib achieved a median progression-free survival (mPFS) of 9.3 months versus 2.0 months for fulvestrant alone, reflecting a 7.3-month improvement. The company plans to submit a New Drug Application for the PIK3CA wild-type cohort in the fourth quarter of 2025. Celcuity is also advancing clinical trials of gedatolisib in other cancer types, including metastatic castration-resistant prostate cancer. As of the third quarter of 2025, the company reported cash and investments of $455 million, projected to fund operations through 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celcuity Inc. unveils new data on gedatolisib for advanced breast cancer in investor presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelcuity Inc. unveils new data on gedatolisib for advanced breast cancer in investor presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a>. unveils new data on gedatolisib for advanced breast cancer in investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Celcuity Inc. has released new data from its Phase 3 VIKTORIA-1 clinical study evaluating gedatolisib in patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer. The study showed that gedatolisib combinations met both primary endpoints by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. Specifically, the triplet combination of gedatolisib, fulvestrant, and palbociclib achieved a median progression-free survival (mPFS) of 9.3 months versus 2.0 months for fulvestrant alone, reflecting a 7.3-month improvement. The company plans to submit a New Drug Application for the PIK3CA wild-type cohort in the fourth quarter of 2025. Celcuity is also advancing clinical trials of gedatolisib in other cancer types, including metastatic castration-resistant prostate cancer. As of the third quarter of 2025, the company reported cash and investments of $455 million, projected to fund operations through 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5jqR2n:1","article_id":"2583263548","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583263548","pubTimestamp":1763074248,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Celcuity Inc. has released new data from its Phase 3 VIKTORIA-1 clinical study evaluating gedatolisib in patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer. The study showed that gedatolisib combinations met both primary endpoints by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. Specifically, the triplet combination of gedatolisib, fulvestrant, and palbociclib achieved a median progression-free survival  of 9.3 months versus 2.0 months for fulvestrant alone, reflecting a 7.3-month improvement. The company plans to submit a New Drug Application for the PIK3CA wild-type cohort in the fourth quarter of 2025. Celcuity is also advancing clinical trials of gedatolisib in other cancer types, including metastatic castration-resistant prostate cancer. As of the third quarter of 2025, the company reported cash and investments of $455 million, projected to fund operations through 2027. You can ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc","BK4139":"生物科技"},"translate_title":"Celcuity Inc.在投资者演示中公布了gedatolisib治疗晚期乳腺癌的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"Celcuity Inc. unveils new data on gedatolisib for advanced breast cancer in investor presentation\n    \n\n        Celcuity Inc. has released new data from its Phase 3 VIKTORIA-1 clinical study evaluating gedatolisib in patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer. The study showed that gedatolisib combinations met both primary endpoints by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. Specifically, the triplet combination of gedatolisib, fulvestrant, and palbociclib achieved a median progression-free survival (mPFS) of 9.3 months versus 2.0 months for fulvestrant alone, reflecting a 7.3-month improvement. The company plans to submit a New Drug Application for the PIK3CA wild-type cohort in the fourth quarter of 2025. Celcuity is also advancing clinical trials of gedatolisib in other cancer types, including metastatic castration-resistant prostate cancer. As of the third quarter of 2025, the company reported cash and investments of $455 million, projected to fund operations through 2027. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}